Skip Navigation



Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Disease Category: Breast Cancer
Location: United States, IL

Clinical Trial Details


Research Study Summary

NSABP B-49 Phase III Study of Docetaxel and Cyclophosphamide Versus Anthracycline-Based Chemotherapy Regimens in Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer


To determine if the docetaxel and cyclophosphamide (TC) regimen is non-inferior to the anthracycline-based chemotherapy regimens in terms of invasive disease-free survival (DFS) by combining B-49 data with the docetaxel, doxorubicin, and cyclophophamide (TAC) and TC arms

Patient Inclusion Criteria:

  • Age ≥ 18 years
  • The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination
  • The breast cancer must be HER2-negative based on current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guideline Recommendations for Human Epidermal
  • Growth Factor Receptor 2 Testing in Breast Cancer
  • If the result of the in situ hybridization testing (fluorescence in situ hybridization [FISH], chromagen in situ hybridization [CISH], or other) is equivocal, the patient is eligible if there is no plan to administer HER2-targeted therapy
  • All of the following staging criteria must be met according to AJCC criteria:
    1. By pathologic evaluation, primary tumor must be pT1-3
    2. By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b

  • If pN0, at least one of the following criteria must be met:
    1. Estrogen receptor (ER) negative AND progesterone receptor (PgR) negative
    2. Pathologic tumor size > 2.0 cm
    3. T1c (pathologic tumor size > 1.0 cm but ≤ 2.0 cm) and ER positive (PgR status may be positive or negative) and either grade 3 histology or Oncotype DX® Recurrence Score of ≥ 25

Patient Exclusion Criteria:

  • None of the following allowed:
    1. No T4 tumors, including inflammatory breast cancer
    2. No definitive clinical or radiologic evidence of metastatic disease
    3. No synchronous or previous contralateral invasive breast cancer (patients with synchronous and/or previous contralateral ductal carcinoma in situ [DCIS] are eligible)
    4. No history of ipsilateral invasive breast cancer or ipsilateral DCIS
    5. Patients must have undergone either a total mastectomy or breast-conserving surgery (lumpectomy)

    To Learn more
  • Phase





    18 and up

    Overall Status


    Facility Type



    Janeen V. Bazan, RN OCN BSN CCRP, Oncology Research Nurse Program Coordinator
    Sherman Health
    1425 North Randall Road
    Elgin, IL 60123
    Phone: 224-783-2907
    Fax: 224-783-3071

    View Map

    If you would like to learn more about participating in this research study, please email the trial contact using the form below.

    Zip/Postal Code:
    Please leave this field empty.

    CW ID: 183098

    Date Last Changed: July 17, 2013

    DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.